Psoriasis drug ESK-001 tested for Long-Term safety in new study

NCT ID NCT05739435

Ongoing Disease control Sponsor: Alumis Inc Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 23 times

Summary

This study looks at the long-term safety and effectiveness of the drug ESK-001 in people with plaque psoriasis who have already taken part in an earlier ESK-001 study. About 165 adults will receive the treatment and be monitored for side effects and how well their skin clears up. The goal is to see if ESK-001 remains safe and helpful over a longer period.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Investigator SIte#1036

Overland Park, Kansas, 66210, United States
Investigator Site # 1006

San Antonio, Texas, 78213, United States
Investigator Site # 1011

Columbus, Indiana, 47201, United States
Investigator Site # 1012

Rapid City, South Dakota, 57702, United States
Investigator Site # 1013

Tampa, Florida, 33614, United States
Investigator Site # 1023

Rogers, Arkansas, 72758, United States
Investigator Site # 1029

Birmingham, Alabama, 35205, United States
Investigator Site # 1041

South Jordan, Utah, 84095, United States
Investigator Site # 2002

Waterloo, Ontario, N2J 1C4, Canada
Investigator Site # 2004

Mississauga, Ontario, L4Y 4C5, Canada
Investigator Site # 2007

North Bay, Ontario, PiB 3Z7, Canada
Investigator Site # 2008

Surrey, British Columbia, V3V 0C6, Canada
Investigator Site # 2010

Québec, Quebec, G1V 4X7, Canada
Investigator Site #1001

Phoenix, Arizona, 85032, United States
Investigator Site #1002

Sherman Oaks, California, 91403, United States
Investigator Site #1005

Rolling Meadows, Illinois, 60008, United States
Investigator Site #1007

Santa Monica, California, 90404, United States
Investigator Site #1010

Clarkston, Michigan, 48346, United States
Investigator Site #1015

Houston, Texas, 77056, United States
Investigator Site #1017

Owensboro, Kentucky, 42301, United States
Investigator Site #1018

Los Angeles, California, 90045, United States
Investigator Site #1019

Portland, Oregon, 97223, United States
Investigator Site #1021

Encinitas, California, 92024, United States
Investigator Site #1022

Philadelphia, Pennsylvania, 19103, United States
Investigator Site #1025

Hialeah, Florida, 33012, United States
Investigator Site #1026

Rockville, Maryland, 20850, United States
Investigator Site #1027

South Bend, Indiana, 46617, United States
Investigator Site #1031

New Brighton, Minnesota, 55112, United States
Investigator Site #1033

Norman, Oklahoma, 73071, United States
Investigator Site #1035

Macon, Georgia, 31217, United States
Investigator Site #1043

Sandy Springs, Georgia, 30328, United States
Investigator Site #2001

Edmonton, Alberta, T6G 1C3, Canada
Investigator Site #2003

Winnipeg, Manitoba, R3M 3Z4, Canada
Investigator Site #2005

Oakville, Ontario, L6J 7W5, Canada
Investigator Site #2006

London, Ontario, N6H 5L5, Canada
Investigator Site #2009

Toronto, Ontario, M3H 5Y8, Canada
Investigator site # 1028

Miami, Florida, 33175, United States
Investigator site # 1030

Fort Lauderdale, Florida, 33308, United States

Conditions

Explore the condition pages connected to this study.

PLAQUE PSORIASIS